INT51831

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1994
Last Reported 2008
Negated 0
Speculated 2
Reported most in Abstract
Documents 20
Total Number 22
Disease Relevance 10.59
Pain Relevance 3.91

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell adhesion (ITGA2B) plasma membrane (ITGA2B)
Anatomy Link Frequency
platelet 11
leukocytes 1
neutrophil 1
ITGA2B (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 38 99.98 Very High Very High Very High
antagonist 28 99.76 Very High Very High Very High
agonist 12 99.06 Very High Very High Very High
ischemia 24 98.24 Very High Very High Very High
Angina 39 96.48 Very High Very High Very High
Morphine 1 94.88 High High
anesthesia 2 90.20 High High
Potency 1 83.24 Quite High
Pain 1 79.96 Quite High
Percutaneous transluminal coronary angioplasty 3 73.84 Quite High
Disease Link Frequency Relevance Heat
Myocardial Infarction 59 99.54 Very High Very High Very High
Thrombosis 40 99.54 Very High Very High Very High
Death 18 99.40 Very High Very High Very High
Adhesions 28 98.24 Very High Very High Very High
Cv Unclassified Under Development 24 98.24 Very High Very High Very High
Acute Coronary Syndrome 38 97.36 Very High Very High Very High
Cv General 3 Under Development 39 96.48 Very High Very High Very High
Syndrome 7 96.16 Very High Very High Very High
Stroke 17 95.80 Very High Very High Very High
Cv General 4 Under Development 3 95.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The study investigated how drug inhibition of the GPIIb/IIIa receptor influences the interactions between platelets and leukocytes.
Spec (investigated) Negative_regulation (inhibition) of GPIIb in platelets
1) Confidence 0.57 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10064007 Disease Relevance 0.25 Pain Relevance 0.08
In general, GPIIb/IIIa blockade seems clinically very promising.
Negative_regulation (blockade) of GPIIb
2) Confidence 0.57 Published 2000 Journal Expert Opin Investig Drugs Section Abstract Doc Link 11060829 Disease Relevance 0.63 Pain Relevance 0.21
Thus, inhibition of GPIIb/IIIa receptor promotes platelet-neutrophil adhesion, but markedly reduces the binding density of platelets in the coaggregates.
Negative_regulation (inhibition) of GPIIb in neutrophil associated with adhesions
3) Confidence 0.57 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10064007 Disease Relevance 0.29 Pain Relevance 0.16
The main findings of this large analysis (n=31,402) was a 9 % reduction in death and MI in patients receiving GP IIb/IIIa inhibitors.
Negative_regulation (inhibitors) of GP IIb associated with myocardial infarction and death
4) Confidence 0.42 Published 2008 Journal Current Cardiology Reviews Section Body Doc Link PMC2801861 Disease Relevance 0.66 Pain Relevance 0.06
It acts as the ethyl ester prodrug of SC-54701, which is a potent (IC50=0.035 microM) and selective inhibitor of GPIIb/IIIa.
Negative_regulation (inhibitor) of GPIIb
5) Confidence 0.42 Published 1998 Journal IDrugs Section Abstract Doc Link 18465540 Disease Relevance 0.43 Pain Relevance 0.21
Inhibitors of the platelet glycoprotein gpIIb/IIIa have been designed, which interfere with the ability of these receptors to bind fibrinogen and thus to form platelet aggregates.
Negative_regulation (Inhibitors) of gpIIb in platelet
6) Confidence 0.42 Published 2002 Journal BMC Cardiovasc Disord Section Body Doc Link PMC117121 Disease Relevance 0.31 Pain Relevance 0
Since it contains the same active ingredient as ReoPro®, Clotinab™ is expected to have the same efficacy as ReoPro® as a platelet GP IIb/IIIa receptor inhibitor.
Negative_regulation (inhibitor) of GP IIb in platelet
7) Confidence 0.42 Published 2008 Journal Yonsei Medical Journal Section Body Doc Link PMC2615343 Disease Relevance 0.61 Pain Relevance 0.09
Platelet glycoprotein IIb/IIIa receptor (GPIIb/IIIa) blockade represents a significant advance in interventional cardiology and treatment of acute ischaemic syndromes.
Negative_regulation (blockade) of GPIIb in Platelet associated with syndrome
8) Confidence 0.42 Published 2000 Journal Expert Opin Investig Drugs Section Abstract Doc Link 11060829 Disease Relevance 0.86 Pain Relevance 0.15
M) resulted in a significantly greater inhibition of the percentage of P-selectin positive platelets by 67.3±4.4% and of activated GPIIb/IIIa to 54.2±2.6%.
Negative_regulation (inhibition) of GPIIb in platelets
9) Confidence 0.41 Published 2006 Journal Purinergic Signal Section Body Doc Link PMC2096644 Disease Relevance 0 Pain Relevance 0.15
GPIIb/IIIa and P-selectin expression on circulating platelets were significantly decreased in the long and the short-term graft preservation group compared with healthy volunteers.
Negative_regulation (decreased) of GPIIb in platelets
10) Confidence 0.41 Published 2003 Journal Clin Transplant Section Abstract Doc Link 14703928 Disease Relevance 0.45 Pain Relevance 0.19
If these analyses prove correct, the cost effectiveness of GPIIb/IIIa receptor therapy for patients with non-ST-segment elevation ACS will also compare favourably with other widely accepted therapies in industrialised countries.
Negative_regulation (effectiveness) of GPIIb associated with acute coronary syndrome
11) Confidence 0.41 Published 2001 Journal Pharmacoeconomics Section Abstract Doc Link 11252545 Disease Relevance 0.77 Pain Relevance 0.10
This consensus group reviewed agents from all three classes (including aspirin, GPIIb/IIIa inhibitors, unfractionated and low-molecular-weight heparins, fibrinolytics, beta-adrenergic blockers, calcium antagonists, nitrates, and morphine) for their overall indication, applicability to the prehospital setting, and current prehospital use.
Negative_regulation (inhibitors) of GPIIb associated with aspirin, antagonist and morphine
12) Confidence 0.41 Published 2001 Journal Prehosp Emerg Care Section Abstract Doc Link 11194071 Disease Relevance 0.89 Pain Relevance 0.42
With lotrafiban, a worldwide large-scale Phase III clinical trial BRAVO (blockage of the GPIIb/IIIa receptor to avoid vascular occlusion) is currently underway.
Negative_regulation (blockage) of GPIIb
13) Confidence 0.41 Published 2000 Journal Expert Opin Investig Drugs Section Abstract Doc Link 11060829 Disease Relevance 0.66 Pain Relevance 0.22
The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy.
Negative_regulation (blockade) of GPIIb in platelet associated with thrombosis
14) Confidence 0.41 Published 1995 Journal Eur. Heart J. Section Title Doc Link 8869013 Disease Relevance 0.36 Pain Relevance 0.06
Positive trends toward decreased thrombotic events have also been observed in patients treated with small molecule inhibitors of GPIIb/IIIa receptors.
Negative_regulation (inhibitors) of GPIIb
15) Confidence 0.41 Published 1996 Journal Haemostasis Section Abstract Doc Link 8979134 Disease Relevance 0.33 Pain Relevance 0.20
The percentage of neutrophils with bound platelets following platelet agonist stimulation was, however, increased following GPIIb/IIIa inhibition.
Negative_regulation (inhibition) of GPIIb in platelet associated with agonist
16) Confidence 0.41 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10064007 Disease Relevance 0.20 Pain Relevance 0.16
Impedance aggregometry responses were oversensitive to GPIIb/IIIa blockade.
Negative_regulation (blockade) of GPIIb
17) Confidence 0.41 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10544919 Disease Relevance 0.09 Pain Relevance 0.28
In addition heparin and particular antiaggregatory drugs inhibiting platelet activation by blocking the GPIIb/IIIa receptor, the common pathway for platelet aggregation, are applied to prevent thrombus formation.
Negative_regulation (blocking) of GPIIb in platelet associated with thrombosis
18) Confidence 0.41 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10695486 Disease Relevance 0.77 Pain Relevance 0.14
Inhibition of fibrinogen binding to platelets by MK-852, a new GPIIb/IIIa antagonist.
Negative_regulation (Inhibition) of GPIIb in platelets associated with antagonist
19) Confidence 0.41 Published 1994 Journal Ups. J. Med. Sci. Section Title Doc Link 7716823 Disease Relevance 0.51 Pain Relevance 0.20
The study investigated how drug inhibition of the GPIIb/IIIa receptor influences the interactions between platelets and leukocytes.
Spec (investigated) Negative_regulation (inhibition) of GPIIb in leukocytes
20) Confidence 0.19 Published 1999 Journal Thromb. Haemost. Section Abstract Doc Link 10064007 Disease Relevance 0.25 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox